Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting
Poster and explanatory video now available on the Company’s website
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that it has presented pre-clinical data describing the novel pre|CISIONTM proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, USA, one of the largest international cancer research meetings.
Proteasome inhibitors are effective anti-cancer drugs that we believe could benefit from application of our preICISIONTM technology to markedly expand their use. While the global proteasome inhibitors market is expected to reach nearly $2.3 billion by 2026, these drugs are primarily indicated for the treatment of multiple myeloma. Severe, dose limiting toxicities have prevented application to a broader range of cancers, in particular to solid tumours.
AVA3996 is the second of Avacta’s pre|CISIONTM chemotherapies. AVA3996 combines a proprietary proteasome inhibitor (called AVA2727D) with Avacta’s pre|CISIONTM tumour targeting chemistry, creating the potential to reduce the systemic toxicities and thereby make it possible to treat solid tumours with a proteasome inhibitor for the first time. AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.
Pre-clinical data generated to date and presented at AACR show that:
· The release of the active proteasome inhibitor (AVA2727D) from AVA3996 is specific to the enzyme FAP, which is upregulated in most solid tumours. This underpins the potential to target the proteasome inhibitor to tumour tissue.
· In a head to head study, AVA2727D kills cancers cells (ex-vivo) as effectively as bortezomib (Takeda’s Velcade) which is one of the approved proteasome inhibitors on the market.
· In three different in-vivo (mouse) cancer models (melanoma, sarcoma and colorectal cancer), AVA3996 was as effective as bortezomib in restricting tumour growth, and in the case of the melanoma model, as effective as trametinib, the standard of care for unresectable melanoma.
· The significant toxicities associated with bortezomib observed in these in-vivo models were not observed in the case of AVA3996, suggesting that the systemic exposure to the drug had been reduced due to the tumour targeting of the pre|CISIONTM chemistry in AVA3996.
The AVA3996 poster presentation, along with an explanatory video reviewing the pre-clinical data are available on the Company’s web site via the links below. The video also reviews the published AVA6000 phase 1a clinical data to date. AVA6000 is the Company’s lead pre|CISIONTM programme that is currently in the later stages of a phase 1a dose escalation safety study.
AVA3996 pre-clinical data poster: https://avacta.com/about/resources/
Dr Alastair Smith, Chief Executive Officer, Avacta Group plc, commented:
“We are delighted with the progress being made in the pre-clinical development of AVA3996, the second drug candidate based on our preICISION TM platform. The potential to apply a proteasome inhibitor to the treatment of solid tumours is very exciting and, as can be seen from our poster presented at the prestigious AACR meeting, the pre-clinical data we are generating is very encouraging in that regard.
We are focused on accelerating AVA3996 through to IND filing as soon as possible so that it can follow AVA6000 into the clinic next year.”
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications Director
Tel: +44 (0) 1904 21 7070
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned